Shares of Guardian Pharmacy Services, Inc. (GRDN) are soaring 6.03% in pre-market trading on Thursday following the release of the company's strong fourth-quarter and full-year 2024 financial results, as well as positive guidance for 2025.

Guardian Pharmacy reported impressive Q4 2024 results, with revenue increasing 20% year-over-year to $339 million and adjusted EBITDA growing 30% to $26 million. The company's resident count grew 14% to approximately 186,000. For the full year 2024, Guardian generated revenue of $1.228 billion, up 17% from the previous year, and adjusted EBITDA of $91 million, representing a 19% increase.

Looking ahead, Guardian Pharmacy provided optimistic guidance for 2025, projecting revenue between $1.33 billion and $1.35 billion, and adjusted EBITDA ranging from $97 million to $101 million. The company's growth strategy, which includes organic expansion, greenfield startups, and strategic acquisitions, has contributed to its strong performance and positive outlook. Additionally, Truist Financial reiterated a Buy rating on GRDN stock, further boosting investor confidence. The company's success in streamlining its COVID and flu vaccination clinics, transforming them from a profitability headwind to a slight tailwind, has also impressed investors and analysts alike.